30 closest matches · ranked by relevance
Waldenström's Macroglobulinemia
Primary: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54 — 68.0; 25.3; 39.7 percentage of…
Waldenström Macroglobulinemia
Primary: Overall Response Rate — 3 Participants
Waldenstrom's Macroglobulinemia
Primary: Major Response Rate — 26 Participants
Waldenstrom's Macroglobulinemia
Primary: Overall Response Rate — 47 percentage of participants
Waldenstrom Macroglobulinemia
Primary: Overall Response Rate — 26 Participants
Waldenstrom's Macroglobulinemia
Primary: Overall Response Rate — 57 Participants
Waldenstrom Macroglobulinaemia
Primary: Number of Participants With Overall Response (OR) for Cycle 1 (Including the Redosing Cycle), as Assessed by the Investigator — 7; 15 participants
Waldenstrom's Macroglobulinemia · Lymphoplasmacytic Lymphoma
Primary: Objective Response Rate — 1; 15; 2; 7 participants
Waldenstrom's Macroglobulinemia
Primary: Number of Participants With Adverse Events — 23 participants
Waldenstrom's Macroglobulinemia
Primary: Overall Response (OR) Rate — 38 percentage of patients
Waldenström's Macroglobulinemia
Primary: Percentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the…
Waldenstrom's Macroglobulinemia
Primary: Overall Response Rate of Bortezomib and Rituximab (VR) in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (WM) — 30 Participants
Waldenstrom's Macroglobulinemia
Primary: Overall Response Rate — 25 Participants
Waldenstrom Macroglobulinemia
Primary: Overall Response Rate (ORR) of Carfilzomib in Bortezomib naïve and Bortezomib-exposed Relapsed WM — 85.7 percentage of participants
Waldenstrom's Macroglobulinemia
Primary: Very Good Partial Response Rate (VGPR) for IDR — 5 Participants
Waldenstrom Macroglobulinemia
Primary: Percentage of Patients Achieving at Least a Major Response Rate at 24 Weeks Post Commencing Treatment — 8 Participants
Waldenström's Macroglobulinemia (WM)
Primary: Major Response Rate (MRR) as Assessed by the Independent Review Committee — 69.8 Percentage of participants — p=<0.0001
Waldenstrom's Macroglobulinemia · Multiple Myeloma
Primary: Percentage of Participants With Complete Response (CR), Partial Response (PR) and Minimal Response (MR) or Minor Response (MinR): (Response Rate) — 7.1; 38.1 percentage…
Waldenstrom Macroglobulinemia
Primary: Overall Response Rate (ORR) According to the Modified Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) Criteria — 87.5 percentage of participants
Waldenstrom Macroglobulinemia
Primary: Overall Response Rate (ORR) — 70.6 Percentage of Participants
Waldenstrom's Macroglobulinemia
Primary: Overall Response Rate of RAD001 in Patients With Previously Untreated WM — 22 participants
Waldenstrom's Macroglobulinemia
Primary: Number of Participants With Adverse Events — 4 Participants
Chronic Lymphocytic Leukemia (CLL) · Waldenstrom Macroglobulinemia (WM)
Primary: Number of Participants With Humoral Response to Vaccination 4 Weeks After the Second Vaccine Administration — 24 Participants
Recurrent Follicular Lymphoma · Recurrent Mantle Cell Lymphoma · Recurrent Marginal Zone Lymphoma
Primary: Phase I: The Maximum Tolerated Dose (MTD) of Temsirolimus in Combination With Bortezomib, Rituximab and Dexamethasone — NA; NA mg
Marginal Zone Lymphoma · Waldenstrom Macroglobulinemia · Non Follicular Indolent Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) as Assessed by Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) and Consensus-Based 6th International Workshop…
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Mantle-Cell Lymphoma
Primary: Phase I: Dose Limiting Toxicities (DLT) Rate — 3; 5; 0; 1 Participants
Marginal Zone Lymphoma
Primary: Overall Rate of Response (ORR) in Participants Receiving Protocol Therapy. — 87.5 percentage of participants